Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,077
  • Shares Outstanding, K 139,000
  • Annual Sales, $ 5,410 K
  • Annual Income, $ -5,330 K
  • 60-Month Beta 1.19
  • Price/Sales 25.95
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.05
  • Number of Estimates 4
  • High Estimate -0.03
  • Low Estimate -0.06
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.55 +67.84%
on 03/25/19
1.85 -50.10%
on 04/02/19
+0.34 (+59.13%)
since 03/22/19
3-Month
0.49 +88.16%
on 03/07/19
1.85 -50.10%
on 04/02/19
-0.85 (-47.85%)
since 01/23/19
52-Week
0.49 +88.16%
on 03/07/19
3.59 -74.29%
on 09/26/18
-1.63 (-63.80%)
since 04/23/18

Most Recent Stories

More News
AVEO FRIDAY DEADLINE ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important April 26th Deadline in Securities Class Action Lawsuit - AVEO

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the "Class...

AVEO : 0.92 (-2.11%)
AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization of FOTIVDA(R) in Spain

AVEO Oncology (NASDAQ:AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the reimbursement approval and commercial...

AVEO : 0.92 (-2.11%)
Class Action Alert CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

AVEO : 0.92 (-2.11%)
CAG : 30.89 (+0.03%)
DPLO : 5.43 (-0.18%)
SHAREHOLDER ALERT: CORT AVEO MBT ARA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

ARA : 6.55 (+8.99%)
CORT : 12.27 (unch)
AVEO : 0.92 (-2.11%)
MBT : 8.09 (+0.62%)
APR 26 DEADLINE NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31,...

AVEO : 0.92 (-2.11%)
CLASS ACTION UPDATE for CORT, AVEO, DPLO and MBT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

CORT : 12.27 (unch)
AVEO : 0.92 (-2.11%)
MBT : 8.09 (+0.62%)
DPLO : 5.43 (-0.18%)
AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why

AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.

BAYRY : 17.3650 (+1.25%)
AVEO : 0.92 (-2.11%)
PDLI : 3.48 (-0.29%)
AZN : 38.69 (-0.15%)
Will AVEO Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in AVEO Pharmaceuticals.

AVEO : 0.92 (-2.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - AVEO

Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. ("Aveo" or the "Company") (NASDAQ: AVEO) and certain of its officers and directors. The class action,...

AVEO : 0.92 (-2.11%)
AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know

AVEO Pharmaceuticals (AVEO) closed at $1 in the latest trading session, marking a -1.96% move from the prior day.

AVEO : 0.92 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AVEO with:

Business Summary

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is...

See More

Key Turning Points

2nd Resistance Point 0.99
1st Resistance Point 0.96
Last Price 0.92
1st Support Level 0.89
2nd Support Level 0.86

See More

52-Week High 3.59
Fibonacci 61.8% 2.41
Fibonacci 50% 2.04
Fibonacci 38.2% 1.67
Last Price 0.92
52-Week Low 0.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar